BioSpace News Archive

Hospital for Special Surgery announced that Bryan T. Kelly, MD, MBA will succeed President and Chief Executive Officer Louis A. Shapiro in a phased transition over the course of 2023, becoming the first surgeon to lead the 160-year-old academic medical system specialized in musculoskeletal health.

A decade ago, the evolution of immuno-oncology transformed the landscape of therapy for patients with many cancers.

Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to develop clinical products modulating gene expression, is pleased to announce the launch of its website, the addition of Andrew Schiermeier, Ph.D to its Board of Directors and the establishment of its Scientific Advisory Board.

Elevated levels of oxidative stress during pregnancy might be linked to a higher risk of preterm birth, according to a new study funded by the Environmental influences on Child Health Outcomes Program at the National Institutes of Health.

MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients with cancer, announces the initiation of coverage of its stock by Kepler Cheuvreux.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”) today announced the grant of an inducement equity award outside ZyVersa’s 2022 Equity Incentive Plan to its newly appointed Chief Medical Officer and Senior Vice President of Medical Affairs, Dr. Pablo Guzman.

GeneDx Holdings Corp. (Nasdaq: WGS) today announced the pricing of offerings for an aggregate of 428,571,429 shares of its Class A common stock at a public offering price of $0.35 per share (the “Offerings”).

ORION CORPORATION announced Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer.

Sol-Gel Technologies, Ltd. announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc.

SK bioscience shared a development history of the South Korea’s first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in the Kingdom of Saudi Arabia (KSA).